Australia: First Patient Dosed in Chemotherapy-Free Soft Tissue Sarcoma Trial.

Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a clinical-stage biotechnology company developing novel LAG-3 immu...

July 31, 2023 | Monday | News
EmVenio Research & TrialHub Partner to Boost Clinical Trial Efficiency

Through TrialHub's data intelligence gathering platform, EmVenio can easily identify optimal markets to attract clinical trial participants who are needed ...

July 28, 2023 | Friday | News
South Korea's PharmAbcine Initiates Phase I Trial of Novel TIE2 Antibody in nAMD"

The study, consisting of single ascending-dose cohort and multiple ascending-dose cohort, has dosed the first of 36 planned study subjects. The Phase I cli...

July 27, 2023 | Thursday | News
Everest Medicines Announces Commercial Launch and First Prescription for XERAVA® in China

Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the development, manufacturing and commercialization ...

July 27, 2023 | Thursday | News
AWS Launches AWS HealthScribe: AI-Powered Clinical Documentation Service

New service leverages speech recognition and generative AI to automatically create preliminary clinical documentation from patient-clinician conversations ...

July 27, 2023 | Thursday | News
Lenacapavir Shows Sustained Impact on HIV Patients' Quality of Life

Analyses Show Oral Bridging Maintains Virologic Suppression When Subcutaneous Lenacapavir Doses are Missed – Gilead Sciences, Inc. (Na...

July 26, 2023 | Wednesday | News
IntelGenx Reports Promising Progress in Montelukast VersaFilm® Collaboration for Parkinson's Disease Treatment

IntelGenx Corp. (TSX:IGX)(OTCQB:IGXT) (the "Company" or "IntelGenx")  announced the execution of a Research Grant Agreement with Karolinska Unive...

July 26, 2023 | Wednesday | News
AstraZeneca's Dapagliflozin Receives Expanded Approval for Heart Failure Treatment in India

AstraZeneca Pharma India has received extended indication approval from the Drugs Controller General of India (DCGI) for its drug, Dapagliflozin in the tre...

July 25, 2023 | Tuesday | News
China's SunHo Initiates Phase I/II Trial for First-in-Class Immunocytokine IBB0979

"We are excited for achieving this important milestone, which also marked the first step to what we hope will ultimately allow us to bring an innovative ca...

July 24, 2023 | Monday | News
Menarini Group Receives Positive CHMP Opinion for ORSERDU® in ER+ Metastatic Breast Cancer

Each year in Europe more than 550,000 patients are diagnosed with breast cancer, of whom 70% have estrogen receptor (ER)-positive disease¹; more tha...

July 24, 2023 | Monday | News
BeiGene's Tislelizumab Receives Positive CHMP Opinion for Advanced ESCC Treatment

“Tislelizumab is the first medicine to come from BeiGene’s immuno-oncology research program and our team partnered with patients, caregivers, a...

July 24, 2023 | Monday | News
Gilead To Discontinue Phase 3 ENHANCE Study of Magrolimab Plus Azacitidine in Higher-Risk MDS

Magrolimab is a potential first-in-class, anti-CD47 immunotherapy with a clinical development program spanning ten potential indications including ongoing ...

July 24, 2023 | Monday | News
Emergent BioSolutions Receives FDA Approval for CYFENDUS™, a Two-Dose Anthrax Vaccine for Post-Exposure Prophylaxis

Emergent BioSolutions Inc. (NYSE:EBS) announced today that the U.S. Food and Drug Administration (FDA) has approved CYFENDUS™ (Anthrax Vaccine Adsorb...

July 21, 2023 | Friday | News
ARMGO Pharma Enrolls First Patient in Phase 2 Trial of ARM210 for Catecholaminergic Polymorphic Ventricular Tachycardia Treatment

Trial to investigate the safety and efficacy of ARM210 for the treatment of Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT) Lead molecule A...

July 21, 2023 | Friday | News

Survey Box

Poll of the Week

Which area of biopharmaceutical research excites you the most?

× Please select an option to participate in the poll.
Processing...
× You have successfully cast your vote.
 {{ optionDetail.option }}  {{ optionDetail.percentage }}%
 {{ optionDetail.percentage }}% Complete
More polls
Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

© 2025 Biopharma Boardroom. All Rights Reserved.

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close